Abstract
Introduction: Breast cancer is considered the most common diagnosed cancer in females in US. It is estimated that 1 in eight females are diagnosed with breast cancer. There are several recognized risk factors that lead to the development of breast cancer. The management of breast cancer involves multidisciplinary one and usually involves surgery, radiation, and systemic therapy. Surgery is the management of breast cancer are still evolving and still considered a major part of the management. It is extremely essential to know that removal of lymph nodes have no treatment benefit to the patient and is used only for staging. The American Society of Clinical Oncology suggests that patients be seen in the clinic every three to six months for the first three years, every six to twelve months in years four and five, and every year afterwards.
In this review, we will discuss the most recent evidence regarding to the diagnosis, treatment, and follow-up of patients with breast cancer for the general surgeon.
Aim of work: In this review, we will discuss the types of surgical treatment for breast cancer
Methodology: We did a systematic search for types of surgical treatment for breast cancer using PubMed search engine (http://www.ncbi.nlm.nih.gov/) and Google Scholar search engine (https://scholar.google.com). We only included full articles.
Conclusions: Breast cancer is a considered one of the most common cancers however it is extremely complex disease. It is recommended that careful consideration should be given to the unique nature of each tumor and patient. Every newly diagnosed breast cancer should be presented at a multidisciplinary meeting to make sure that optimal treatment plan is carried out by all specialties involved. The American Society of Clinical Oncology suggests that patients be seen in the clinic every three to six months for the first three years, every six to twelve months in years four and five, and every year afterwards. Treatment for breast cancer will continue to develop; further improvements in outcomes will likely be based on the development of targeted therapies.